2019 ACR/AF指南:JIA相关葡萄膜炎的筛查、监测与治疗
该指南由美国风湿病学会与关节炎基金会制定,针对幼年特发性关节炎(JIA)患儿葡萄膜炎的筛查、监测和治疗提出推荐。基于系统文献综述和GRADE方法,因高质量证据缺乏,推荐结合现有证据与专家共识形成。推荐定期眼科筛查和监测,初始局部糖皮质激素治疗,系统治疗时使用甲氨蝶呤及TNF抑制剂(阿达木单抗、英夫利西单抗)。
要点
- JIA患儿应定期眼科筛查,频率基于个体风险因素。
- 葡萄膜炎患儿应定期眼科监测,间隔基于眼部检查与治疗方案。
- 初始治疗用局部糖皮质激素;系统治疗推荐甲氨蝶呤、阿达木单抗、英夫利西单抗。
核心结论
- 指南为JIA相关葡萄膜炎的筛查、监测和管理提供方向,基于GRADE方法和共识过程。
研究设计与样本
- 由儿科风湿病学家、葡萄膜炎眼科专家、患者代表和方法学家生成关键临床问题,经系统文献综述和GRADE证据评级,共识过程形成推荐。
主要发现
- 因缺乏高质量证据,推荐基于现有证据和共识专家意见。
- 推荐定期眼科筛查JIA患儿,频率基于个体风险因素。
- 推荐定期眼科监测葡萄膜炎患儿,间隔基于眼部检查发现和治疗方案。
- 初始治疗推荐局部糖皮质激素以控制炎症。
- 需要系统治疗时推荐甲氨蝶呤和TNF抑制剂阿达木单抗、英夫利西单抗。
关键数值与推荐
- 眼科监测推荐为强推荐,主要因监测不频繁可能导致威胁视力的并发症。
- 推荐及时加用非生物和生物制剂以维持持续视力丧失风险患儿的葡萄膜炎控制。
临床怎么用
- 临床中应定期筛查JIA患儿葡萄膜炎,根据个体风险因素确定频率。
- 对葡萄膜炎患儿定期监测,根据眼部检查与治疗方案调整间隔。
- 初始局部糖皮质激素治疗,系统治疗时选用甲氨蝶呤或TNF抑制剂。
局限性
- 缺乏高质量证据,推荐主要基于共识专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA). METHODS: Pediatric rheumatologists, ophthalmologists with expertise in uveitis, patient representatives, and methodologists generated key clinical questions to be addressed by this guideline. This was followed by a systematic literature review and rating of the available evidence according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. A group consensus process was used to compose the final recommendations and grade their strength as conditional or strong. RESULTS: Due to a lack of literature with good quality of evidence, recommendations were formulated on the basis of available evidence and a consensus expert opinion. Regular ophthalmic screening of children with JIA is recommended because of the risk of uveitis, and the frequency of screening should be based on individual risk factors. Regular ophthalmic monitoring of children with uveitis is recommended, and intervals should be based on ocular examination findings and treatment regimen. Ophthalmic monitoring recommendations were strong primarily because of concerns of vision-threatening complications of uveitis with infrequent monitoring. Topical glucocorticoids should be used as initial treatment to achieve control of inflammation. Methotrexate and the monoclonal antibody tumor necrosis factor inhibitors adalimumab and infliximab are recommended when systemic treatment is needed for the management of uveitis. The timely addition of nonbiologic and biologic drugs is recommended to maintain uveitis control in children who are at continued risk of vision loss. CONCLUSION: This guideline provides direction for clinicians and patients/parents making decisions on the screening, monitoring, and management of children with JIA and uveitis, using GRADE methodology and informed by a consensus process with input from rheumatology and ophthalmology experts, current literature, and patient/parent preferences and values.
引用
- Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019. PMID: 31021540. doi:10.1002/acr.23871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。